Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis
Open Access
- 1 October 2019
- journal article
- Published by Elsevier in JAAD Case Reports
- Vol. 5 (10) , 928-930
Abstract
No abstract availableKeywords
Funding Information
- Amgen
- Janssen
- Novartis
- Sanofi
- Regeneron
- Pfizer
This publication has 7 references indexed in Scilit:
- Successful Treatment of Refractory Plaque-Type Psoriasis and Psoriatic Arthritis With Guselkumab and Adalimumab Combination Therapy: A Case Report2019
- Phase II Study of ABT‐122, a Tumor Necrosis Factor– and Interleukin‐17A–Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to MethotrexateArthritis & Rheumatology, 2018
- Combination biologic therapy for the treatment of severe palmoplantar pustulosisJAAD Case Reports, 2017
- Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational studyBritish Journal of Dermatology, 2016
- Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis: A case reportJAAD Case Reports, 2015
- Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center.2013
- Combination Biologic Treatment of Refractory Psoriasis and Psoriatic ArthritisThe Journal of Rheumatology, 2012